"The U.S. Food and Drug Administration today approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
Patients should be counseled that antibacterial drugs including HIPREX (methenamine hippurate) should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When HIPREX (methenamine hippurate) is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by HIPREX (methenamine hippurate) or other antibacterial drugs in the future.
Last reviewed on RxList: 8/14/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Hiprex Information
Hiprex - User Reviews
Hiprex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.